Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14440671 | 0.83 | TET2 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL21488436 | 0.81 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL23366306 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL22892465 | 0.78 | CA14 (0.50) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL16691200 | 0.78 | GAA (0.53) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL1460181 | 0.77 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL16685278 | 0.76 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL865926 | 0.76 | — | — | |
| SCHEMBL7771621 | 0.75 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL9138159 | 0.75 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230079833-A1 | GALACTOSE-LINKED MULTIMERIC GLYCOMIMETIC INHIBITORS OF E-SELECTINS, GALECTIN-3, AND/OR CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20220265693-A1 | USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS | GLYCOMIMETICS, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220265691-A1 | METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES | GLYCOMIMETICS, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220220144-A1 | MULTIMERIC PAN-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| EP-4003367-A1 | USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS | GlycoMimetics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3997247-A1 | METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES | GlycoMimetics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114401726-A | Use of E-selectin antagonists to improve survival of reconstituted bone marrow depleted hosts | 糖模拟物有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114341368-A | Methods of using gene expression as an indicator of E-selectin inhibitor efficacy and clinical outcome for multiple tumor types | 糖模拟物有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114340736-A | Galactose-linked multimeric glycomimetic inhibitors of E-selectin, galectin-3 and/or CXCR4 chemokine receptors | 糖模拟物有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3958978-A1 | GALACTOSE-LINKED MULTIMERIC GLYCOMIMETIC INHIBITORS OF E-SELECTINS, GALECTIN-3, AND/OR CXCR4 CHEMOKINE RECEPTORS | GlycoMimetics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-113801178-A | Dual targeting compounds for inhibition of E-selectin and CXCR4 chemokine receptors | 梁玉增 | 2021-12-17 | — | — | CN | disclosed |
| EP-3911307-A1 | SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY | GlycoMimetics, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3893936-A2 | METHODS OF TREATING HIV AND AIDS AND THE ELIMINATION OF LATENT RESERVOIRS OF HIV INFECTION USING SELECTIN, GALECTIN, AND SIGLEC ANTAGONISTS | GlycoMimetics, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2021022132-A1 | USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS | MAGNANI JOHN L (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021011435-A1 | METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES | MAGNANI JOHN L (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2020219417-A1 | GALACTOSE-LINKED MULTIMERIC GLYCOMIMETIC INHIBITORS OF E-SELECTINS, GALECTIN-3, AND/OR CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219419-A1 | MULTIMERIC PAN–SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020150263-A1 | SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY | MAGNANI JOHN L (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020123435-A2 | METHODS OF TREATING HIV AND AIDS AND THE ELIMINATION OF LATENT RESERVOIRS OF HIV INFECTION USING SELECTIN, GALECTIN, AND SIGLEC ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265693-A1 | USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS | SELE, SELPLG, SELL | ALDH1A1 469/4885SMN1; SMN2 1159/4885POLB 3966/4885 |
| US-20230079833-A1 | GALACTOSE-LINKED MULTIMERIC GLYCOMIMETIC INHIBITORS OF E-SELECTINS, GALECTIN-3, AND/OR CXCR4 CHEMOKINE RECEPTORS | LGALS3, LGALS1, CXCR4 | ALDH1A1 1188/4885SMN1; SMN2 3809/4885POLB 4690/4885 |
| US-20220220144-A1 | MULTIMERIC PAN-SELECTIN ANTAGONISTS | SELE, SELP, BSG | ALDH1A1 1387/4885SMN1; SMN2 3439/4885POLB 4646/4885 |
| US-20220265691-A1 | METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES | SIGLEC7, FUT7, FUT4 | ALDH1A1 568/4885SMN1; SMN2 4557/4885POLB 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.